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Purpose: To assess the efficacy and safety of a single injection of a new formulation of 
hyaluronic acid (MPS-HA2%) in patients with symptomatic knee osteoarthritis after 12 
months’ follow-up.
Patients and Methods: Prospective, single-arm, multicentre, open-label, 12-month follow-up 
study. Patients with Kellgren–Lawrence (KL) 2–3 and visual analogue scale (VAS) pain scores of 
≥40–< 80 mm received a single injection of MPS-HA2%. The primary outcome was the reduction 
in VAS pain scores from baseline, and the secondary outcomes were the Western Ontario and 
McMaster (WOMAC) Universities Osteoarthritis Index, the minimum clinically important 
improvement (MCII), and patient and investigator global assessments (PGA, IGA) measured on 
5-point Likert scale. Adverse events were recorded throughout the study for safety purposes.
Results: A total of 101 patients (mean age: 68 years; 74% female; and 78% overweight) 
were included. The mean reduction in pain at 12 months was 37.7%; the total WOMAC 
score improved by 36.5% and the pain, stiffness and physical function subscores returned 
improvements of 32.1%, 34.1% and 32.7%, respectively (p=0.0001 with respect to baseline). 
At 12 months, a statistically significant 62.2% of patients obtained an improvement equal to 
or greater than the MCII. The mean PGA score at baseline was 2.44 and 1.46 at 12 months 
(p<0.05), and the mean IGA scores at equivalent timepoints were 2.29 and 1.48 (p<0.05). 
Fourteen patients received a second injection at the 6-month follow-up visit. Eight patients 
reported a total of 12 treatment-related adverse events that were local, non-serious and of 
mild-to-moderate intensity.
Conclusion: With just a single intra-articular injection, this not controlled trial suggests that 
MPS-HA2% is effective 12 months after the procedure in most cases. Patient tolerability and 
safety were both optimal (NCT03852914).
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Introduction
Osteoarthritis (OA) of the knee is a common joint disorder in which progressive 
cartilage destruction, osteophyte formation, subchondral sclerosis and synovitis 
lead to articular degeneration.1–3 It is a multifactorial disease with genetic altera-
tions, gender and ageing playing crucial roles in the processes associated with 
cartilage and joint degeneration and therefore in the development of OA.4,5 The 
main manifestations include pain, physical dysfunction and markedly reduced 
quality of life.6 It constitutes a high socioeconomic burden, with joint replacement 
responsible for most of the direct healthcare costs, besides the indirect costs arising 
from productivity losses, premature death and early retirement.7 Due to the 
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multifactorial nature, the different treatment targets and 
high frequency of associated comorbidities, researchers 
are yet to identify the ideal therapy for OA. This has led 
to a long-term multimodal approach including different 
pharmacological and nonpharmacological therapeutic 
interventions depending on the stage of the disease and 
each patient’s characteristics.4,5,7–9
Hyaluronic acid (HA) is a naturally occurring polysac-
charide found within synovial fluid and produced by type- 
B synoviocytes, fibroblasts and chondrocytes; it is widely 
distributed in connective tissues and a primary component 
of articular fluid. It provides nutrients for articular carti-
lage, lubricates articulation and absorbs strains. The mole-
cular weight (MW) and rheological properties of the HA 
in the synovial cavity change as we age and in the case of 
joint disorders.10
Viscosupplementation of the synovial fluid with 
intra-articular HA injections was first included in the 
therapeutic arsenal at the end of the 20th century, with 
the intention being to restore the concentration and 
molecular weight distribution of HA in the synovial 
fluid. However, there is now evidence that the clinical 
benefit of HA in OA is not only due to its mechanical 
properties; several studies have found that it also exerts 
a chondroprotective effect, promotes proteoglycan and 
glycosaminoglycan synthesis, and has anti-inflammatory, 
mechanical, subchondral and analgesic properties.11 
Despite some discrepancies between scientific societies 
regarding the widespread use of intra-articular HA to 
treat knee OA, several systematic reviews and meta- 
analyses published recently concluded that viscosupple-
mentation is a viable treatment option that provides 
a clinically important reduction in pain and improve-
ment in function.12–19 This is especially true when the 
treatment is adequately tailored according to patient 
characteristics,20,21 with effects lasting more than those 
of intra-articular corticosteroids22–26 and with a better 
safety profile than other treatments for OA.19,24,27–30
Treatment with HA has traditionally consisted of sev-
eral intra-articular injections administered at weekly inter-
vals. However, there is an ever-increasing demand for 
shorter treatments, resulting in less visits and costs for 
both patients and healthcare providers. Furthermore, the 
use of single-dose treatments would reduce the potential 
risk of local adverse events related to the administration 
procedure. Different approaches have been developed in 
order to obtain effects that are as durable as those of 
multiple-injection treatments, such as greater injection 
volumes, higher concentrations, changes in the molecular 
structure (crosslinking) or the inclusion of different addi-
tives, but there is still no clear consensus about the impact 
of these modifications on the clinical results.31
Most studies of knee OA involving single-injection 
products were designed to follow the patients for no 
more than 6 months;32 therefore, in most cases, the scar-
city of results makes it hard to comment on the long-term 
duration of the effects.
The SOYA (Symptomatic Osteoarthritis one Year 
Assessment) study was designed to investigate the efficacy 
and safety of a new formulation of HA in the treatment of 
patients with symptomatic knee OA, focusing particularly 
on the effects 12 months after a single injection.
Patients and Methods
Ethics and Registration
The trial was conducted in accordance with Good Clinical 
Practices and in compliance with the principles of the 
Declaration of Helsinki. Approval was obtained from the 
Alcorcón Hospital Institutional Review Board (Alcorcón, 
Madrid, Spain) (approved on 6th of September 2018, min-
utes nº 10/18) and the Spanish Agency of Medicines and 
Medical Devices. All patients provided their written 
informed consent to participate in this trial. The study 
was registered at ClinicalTrials.gov with the identifier 
NCT03852914.
Design
The study followed a prospective, single-arm, open-label 
design with a 12-month follow-up. Patients deemed eligi-
ble at screening completed a 14-day washout period prior 
to administration. Each patient then received a single intra- 
articular injection of MPS-HA2%, a new product consist-
ing of a 2% wt./vol solution of medium MW (1000 kDa)33 
HA obtained by fermentation and without any chemical 
modification, dosed in pre-filled syringes containing 98 mg 
of HA. Patients were followed for 12 months, with 
a telephone contact at 3 months for safety purposes and 
follow-up visits at 6 and 12 months (Figure 1). At 6 
months, patients were offered a second injection if and 
when they met all the criteria established for re-treatment 
: 1) a reduction in pain from baseline on VAS < MCII; 2) 
the patient’s overall opinion; and 3) no treatment-related 
adverse events after the first administration; and were 
followed until completion of the initial 12 month period. 
Only paracetamol (up to 3 g/day) was permitted as rescue 
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medication for OA pain during the study and it had to be 
discontinued at least 24 h before visits.
Study Population
Eligible patients were men and women aged ≥ 45 years 
who met the following inclusion criteria: diagnosis of 
primary OA of the knee in the medial/lateral tibiofemoral 
compartment according to ACR criteria;34 radiological 
grade 2–3 according to the Kellgren and Lawrence (KL) 
scale35 confirmed by an anteroposterior X-ray; and VAS 
pain scores ≥ 40 – < 80 mm in the target knee and ≤ 
20 mm in the contralateral knee. Patients had to be able to 
understand and comply with the study procedures and give 
their written consent to participate before entering in the 
study.
Exclusion criteria comprised a body mass index (BMI) 
≥ 30 kg/m2, a severe varus/valgus deformity (>15°) or 
patellofemoral pain/syndrome, previous surgery in the tar-
get knee including arthroscopy within the past year, severe 
inflammation of the target knee, an inflammatory joint 
disease, significant OA in other joints requiring pharma-
cological treatment, venous or lymphatic stasis in the 
relevant limb. Patients with the following treatments 
were also excluded: intra-articular HA (within the 
last year), intra-articular corticosteroids or joint lavage 
(last 3 months) and symptomatic slow-acting drugs for 
OA (SYSADOA). Finally, patients could not participate 
if they had known hypersensitivity to HA or paracetamol, 
were pregnant or breastfeeding, or if they were on 
a waiting list for surgery or awaiting a disability 
assessment.
Outcome Measures
We used patient-reported outcomes and derived measures 
to evaluate the efficacy of the treatment. The primary 
endpoint was a reduction in pain intensity measured on 
a 0–100 mm VAS, where 0 was the absence of pain and 
100 was extreme pain. Secondary variables included the 
Western Ontario and McMaster (WOMAC) Universities 
Osteoarthritis Index total and subscale scores for pain 
(WOMAC A), stiffness (WOMAC B) and physical func-
tion (WOMAC C); all were measured on a VAS and 
normalized. Similarly, the percentage of patients who 
achieved the minimum clinically important improvement 
(MCII),36 defined as a relative improvement over baseline 
of ≥ 20% in VAS scores, was another secondary endpoint. 
The patient global assessment (PGA) and investigator 
global assessment (IGA) were measured on a 5-point 
Likert scale where 0 was the best condition and 4 the 
worst. Adverse events (AEs) were recorded from screen-
ing until the end of the study.
Statistics
A sample size of at least 93 patients was necessary to 
provide sufficient evidence that MPS-HA2% is effective 
in the treatment of knee OA with a 90% power and con-
sidering a dropout rate of 35% after 12 months’ follow-up.
The statistical and dataset analyses were defined in the 
Statistical Analysis Plan. We considered the results in 
terms of three populations. The modified intention-to- 
treat (mITT) population included all patients who received 
at least one dose of study treatment and completed at least 
one post-baseline efficacy assessment. The per-protocol 
Figure 1 Study schedule.
Journal of Pain Research 2021:14                                                                                                     https://doi.org/10.2147/JPR.S321841                                                                                                                                                                                                                       
DovePress                                                                                                                       
2231
Dovepress                                                                                                                                                            Gavín et al
Powered by TCPDF (www.tcpdf.org)
(PP) population included all patients who completed the 
study without any major protocol deviations. Finally, the 
safety population comprised all patients who received at 
least one dose of the study treatment. The main study 
population for the analysis was the mITT, although the 
PP population was also analysed.
Quantitative variables were reported as mean, median, 
standard deviation, interquartile range, minimum, maximum 
and the total number of patients with available data. 
Qualitative variables were described through their distribu-
tion of absolute and relative frequencies. Student’s t-test or 
Wilcoxon nonparametric tests were used depending on the 
type and distribution of each dataset.
The statistical analysis was performed with SAS® v9.3 
and significance was set at p<0.05.
Results
Patient Disposition
Seven Spanish hospitals participated in the study between 
January 2019 and May 2020 and preselected 104 patients 
of whom three were found to be ineligible. Finally, 101 
patients were included and a total of 83 (82.2%) completed 
the 12-month follow-up. The mITT population comprised 
98 patients that received the study treatment and com-
pleted at least one post-baseline assessment. At 12 months, 
the PP population consisted of 74 patients who had com-
pleted the 12-month follow-up without any major protocol 
deviations. Of the 101 eligible patients, 17 did not com-
plete the study: 2 cases were due to AEs (neither were 
study related), 6 patients decided to dropout, and 9 were 
withdrawn because of protocol violations. One additional 
patient was lost to follow-up. The CONSORT flow dia-
gram of the trial is shown in Figure 2.
Demographic and Baseline 
Characteristics
The patients had a mean age of 68 years and 50% were 
between 63 and 74 years old. The female/male ratio was 
approximately 3/1 and 98% of the patients were 
Caucasian. With respect to occupations, 51.49% of the 
patients were retired, 25.74% were homemakers and 
19.80% were employed in different professions (infor-
mation on occupation was unavailable for 3 patients). 
The sample had a mean weight of 71.56 kg and a height 
of 1.62 m. The mean BMI was 27.05 kg/m2 and 78.22% 
of the patients were overweight. Nearly two-thirds 
(65.35%) of the sample had three or more comorbidities 
and only 4% reported having no concomitant diseases. 
The most common comorbidities at inclusion were 
either related to the cardiovascular system or metabolic 
diseases, with frequencies of 60.40% and 53.47%, 
respectively.
The mean time elapsed since the diagnosis of OA was 4.1 
years (range: 1–28 years). Regarding the KL radiological 
grade, 57.4% of the subjects were grade 3. Knee OA was 
unilateral in 26.70% of cases. All patients had predominantly 
tibiofemoral OA, while 62.38% also had some degree of 
patellofemoral compromise. Almost one-fifth (18.81%) of 
patients had previously undergone surgery on the target 
knee (arthroscopy in 12 patients and meniscectomy in 7 
others). The mean time since this surgery was 14.1 years.
Symptoms at baseline were moderate-to-severe, as 
determined through VAS pain scores, total WOMAC and 
WOMAC subscales A, B and C, as shown in Table 1.
Patients received one intra-articular injection of MPS- 
HA2% via a superolateral (45.54%), lateral (41.58%) or 
medial (11.88%) approach.
Figure 2 Flow diagram of the study.
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Efficacy Results
For the mITT population, the mean overall pain score 
(primary outcome) was 63.57 mm at baseline. By 6 
months pain scores had reduced to a mean of 
37.59 mm, and this improvement was sustained over 
time with a mean score of 38.37 mm at 12 months. 
Very similar values were obtained among the PP popu-
lation, with a mean pain scores of 63.82 mm at base-
line and 36.97 mm and 36.61 mm at 6 and 12 months, 
respectively. These reductions were statistically signif-
icant (p<0.0001) and well above the 20% established 
as clinically relevant (Table 2).
Significant improvements were also observed in the 
total WOMAC score and the pain, stiffness and function 
subscales for both the mITT and PP populations; again, the 
improvement reported at 6 months was maintained at 12 
months (Table 2).
The percentage of mITT patients who achieved MCII 
based on their VAS pain scores was 66.33% and 62.24% at 
6 and 12 months, respectively. The equivalent figures in 
the PP population were 68.54% and 66.22%.
The mean PGA score in the mITT population was 2.44 
at baseline, 1.35 at 6 months and 1.46 at 12 months 
(p<0.05). The scores were very similar for the PP popula-
tion and the PGA improved significantly (p<0.05) at the 
end of the study. As for the IGA among the mITT popula-
tion, the mean score was 2.29 at baseline, 1.06 at 6 months 
and 1.48 at 12 months (p<0.05). Staying with the mITT 
sample, the PGA was “better” or “much better” for 
66.33% of patients after 6 months and 56.12% at 12 
months. In the PP population the figures were very similar, 
with a result of better/much better reported by 67.42% of 
patients at 6 months and 62.16% at 12 months. 
Investigators rated the patients’ condition as better/much 
better for 71.42% of cases at 6 months and 56.13% after 
12 months’ follow-up. The figures were very similar for 
the PP population where the IGA was better/much better 
for 74.16% of patients at 6 months and 63.51% at 12 
months.
The additional analyses revealed that normal weight 
patients responded better to the treatment than overweight 
patients, although the differences did not reach statistical 
significance (p>0.05). On the other hand, a greater 
improvement was noted at 6 months in patients with KL 
grade 2 compared to grade 3; the differences within groups 
for most of the parameters studied reached statistical sig-
nificance at 6 months but not at 12 months. We also 
examined if there were any differences in the responses 
that could be attributed to the approach used for the injec-
tion. A significant (p<0.05) and clinically relevant reduc-
tion compared to baseline was observed for each approach. 
Greater improvements were evidenced in patients adminis-
tered the treatment via a medial route, although the low 
number of patients treated meant the differences between 
the three approaches were not statistically significant 
(p>0.05).
A total of 14 patients who met the protocol retreatment 
criteria received a second injection at the 6-month visit 
and were followed for another 6 months until the end of 
Table 1 Demographic and Baseline Characteristics of Eligible 
Patients (n=101)
Mean (SD) n (%)
Women 75 (74.26%)
Age (years) 68.04 (9.05)
BMI (kg/m2) 27.05 (2.68)
Underweight 1 (0.99%)




Cardiovascular system 61 (60.40%)
Metabolic and nutrition disorders 54 (53.47%)
Musculoskeletal and connective 
tissue disorders
34 (33.66%)
Nervous system 32 (31.68%)
Time since OA diagnosis (years) 4.14 (5.09)
Target knee (right) n (%) 58 (57.43%)
Kellgren–Lawrence grade of target knee
Grade 2 43 (42.57%)
Grade 3 58 (57.43%)
VAS pain (mm) 63.86 (11.60)
WOMAC (mm)
Total 50.53 (16.70)
Pain (A) 49.81 (17.42)
Stiffness (B) 49.52 (21.60)
Function (C) 52.25 (17.75)
Note: *This patient was excluded after confirming their BMI. 
Abbreviations: SD, standard deviation; BMI, body mass index; VAS, visual analogue 
scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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the study. Six months after the second injection the mean 
reduction of pain in this group was 24.02% (p<0.05) and 
50% of the group achieved MCII.
Six patients discontinued the study prematurely of their 
own accord due to a lack of expected response, three from the 
mITT population and the other three only belonged to the 
safety population as they had not completed a post-baseline 
assessment. Using the median study duration until dropout as 
an estimator of treatment efficacy, in this group of patients the 
treatment was effective for just over 5 months (5.29 months).
At the 12-month visit, almost 47% of the patients 
reported having taken paracetamol as rescue medication 
at some point during the follow-up period.
Safety Results
A total of 12 treatment-related adverse events were 
reported involving eight patients (7.9%). These adverse 
events were all local, of mild-to-moderate intensity and 
classified as non-serious. No treatment-related adverse 
events were reported after the second injection. No serious 
treatment-related adverse events were reported throughout 
the overall study period.
Discussion
Viscosupplementation is a recognised treatment for OA in 
different joints. Several systematic reviews and meta- 
analyses advocate its use in terms of efficacy and 
safety11,13,16–19,21,24,27,29 and, unlike other treatments 
such as oral drugs, HA is free from drug–product interac-
tions and problems associated with compliance or the risks 
of overuse.37 The most widespread use of HA is in knee 
OA, and although they were initially administered in 
cycles of 3–5 injections, HA products based on a single 
injection have been in demand for some time. Since the 
effects of HA were believed to last for 6 months,38,39 very 
few studies have been conducted with single-injection 
products and follow-up periods lasting more than 6 
months. Considering this background, after confirming 
the biocompatibility of MPS-HA2%,40 our objective was 
to study its efficacy and safety in patients with sympto-
matic knee OA for 1 year after a single injection.
The results suggest that MPS-HA2% is effective in 
relieving pain and improving function. The reduction of 
VAS pain at 6 months was significant compared to base-
line and lasted for the whole follow-up period with relative 
reductions ranging from 37.67% to 41.01%. Significant 
Table 2 Efficacy Results at 6 and 12 Months
Outcome 6 Months 12 Months
mITT (n=98) PP (n=81) mITT (n=98) PP (n=74)
Pain (% change from baseline)
Mean (SD) −39.74* (4.78) −41.01* (4.87) −37.67* (5.11) −40.81* (5.38)
95% CI (−49.23; −30.25) (−50.68; −31.34) (−47.82; −27.52) (−51.54; −30.08)
WOMAC (% Change from baseline)
WOMAC total mean (SD) −36.57* (4.63) −37.53* (4.72) −36.47* (4.91) −40.69* (5.09)
95% CI (−45.77; −27.37) (−46.91; −28.14) (−46.20; −26.73) (−50.84; −30.54)
WOMAC pain mean (SD) −32.92* (5.27) −33.40* (5.44) −32.07* (5.60) −35.97* (6.00)
95% CI (−43.37; −22.46) (−44.22; −22.59) (−43.19; −20.95) (−47.93; −24.00)
WOMAC stiffness mean (SD) −35.24& (9.05) −33.60# (9.85) −34.08* (7.67) −34.93* (9.31)
95% CI (−53.22; −17.23) (−53.18; −14.01) (−49.30; 18.86) (−53.49; −16.37)
WOMAC function mean (SD) −33.95* (4.81) −33.33* (5.12) −32.71* (5.08) −39.18* (4.88)
95% CI (−43.49; −24.40) (−43.49; −23.16) (−42.80; −22.62) (−48.91; −29.44)
MCII n (%) 65 (66.33) 61 (68.54) 61 (62.24) 49 (66.22)
PGA (much better/better) n (%) 65 (66.33) 60 (67.42) 55 (56.12) 46 (62.16)
IGA (much better/better) n (%) 70 (71.42) 66 (74.16) 55 (56.13) 47 63.51)
Note: *p<0.0001; &p=0.0002; #p=0.0010. 
Abbreviations: mITT, Modified Intention to Treat; PP, per protocol; SD, standard deviation; CI, confidence interval; WOMAC, Western Ontario and McMaster Universities 
Osteoarthritis Index; MCII, minimally clinical important improvement; PGA, patient global assessment; IGA, investigator global assessment.
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improvements were also observed in WOMAC scores (A, 
B, C and total) with improvements ranging from 32.07% 
to 40.69% for the 12-month follow-up period; these results 
are well above the 20% considered as clinically relevant.16 
After 6 months, 66.33% of patients achieved MCII and by 
12 months this value was 62.24%. The patient and inves-
tigator global assessments followed a similar pattern.
Patient retention is a point of concern in clinical trials, 
especially long-term studies.41 In our study, the required 
sample size was estimated considering an expected drop-
out rate of 35% throughout the entire study period; there-
fore, a discontinuation rate of 18% after 12 months’ 
follow-up can be considered a good result that was prob-
ably due to the efficacy and tolerability of the treatment.
One of the keys to viscosupplementation is the correct 
identification of the patient characteristics that may be 
associated with a better response. Obesity and a high 
radiographic grade have been identified as predictors of 
viscosupplementation failure.42–44 Consequently, HA 
administration to obese patients and those with more 
severe grades of knee OA has frequently been discour-
aged. However, more recent studies have concluded that 
while these patients may have a reduced possibility of 
a positive response to HA treatment, the benefits 
obtained in those who do respond are similar to those 
of normal weight subjects and with mild/moderate OA.45 
Although our study did not include obese patients, about 
80% of our sample were overweight and we did not find 
significant differences in the response rates between 
overweight and normal or underweight patients. On the 
other hand, when considering the grade of OA, we found 
differences in some of the response parameters at 6 
months but not after 12 months. As such, given there 
are very few effective and well-tolerated treatment 
options for OA, we share the opinion of most recent 
publications in that HA should not be ruled out as 
a therapeutic option for these patients because 
a substantial number can benefit from it.
Intra-articular injections can be administered via sev-
eral approaches, and different outcomes have been 
reported in terms of efficacy and local reactions.46–48 In 
the present study the protocol did not specify the approach 
to be used and each investigator administered the treat-
ment according to their own judgement and experience. 
The superolateral and lateral approaches were used in 
a similar number of patients, whereas the medial route 
was much less frequent. Although greater improvements 
were observed for patients treated via the medial approach, 
the reduced number of subjects meant the differences 
between groups were not statistically significant and the 
results should be considered with caution.
Just 14% of the patients received a second, single 
injection at 6 months and were followed for another 6 
months, going on to record a clinically important improve-
ment in pain and function and confirm that clinical out-
comes can be improved by repeating HA administration if 
the symptoms reappear.19,49–52
With respect to safety, a single injection of MPS-HA2 
% was well tolerated and only 8 patients reported local, 
treatment-related adverse events. These adverse events 
were consistent with those commonly described for this 
class of products and none were serious.
The limitations of this study include the open-label 
design without a direct comparator arm. With regard to 
the possibility of a head-to-head design, we could not find 
any controlled trials with single-injection HA products that 
would have demonstrated 12-month efficacy in 
a significant number of patients.
Another limitation is due to the fact that although all 
our patients had predominantly tibiofemoral compromise, 
a significative percentage presented some degree of patel-
lofemoral affectation. This could be a source of bias as 
patellofemoral involvement could lead to worse efficacy 
results,14,53 so many studies exclude these patients. The 
inclusion of purely tibiofemoral patients may have resulted 
in even better results, although we consider that our patient 
sample is a better reflection of the real situation.
Conclusions
The results of this study suggest that a single injection of 
MPS-HA2% provides long lasting improvement in 
patients with mild to moderate knee OA but further con-
trolled trials must be performed to confirm or infirm these 
promising data. Patient tolerability and safety were both 
optimal.
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